In previous reports, we had shown that combined SHP2 inhibition restores sensitivity to RAS-MAPK or PI3K inhibitors in neuroblastoma and other pediatric malignancies harboring NRAS or PI3K mutations (30, 59), thus informing further development of potentially useful treatment regimens for patients with relapsed neuroblastoma based on the genetic profile of their tumors. The gene discussed is NRAS; the disease is neuroblastoma.